Daniel Gonzalez1, James M Chamberlain2, Jeffrey T Guptill3,4, Michael Cohen-Wolkowiez3,4, Barrie Harper3, Jian Zhao5, Edmund V Capparelli6. 1. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Division of Emergency Medicine, Children's National Medical Center, Washington, DC, USA. 3. Duke Clinical Research Institute, Durham, NC, USA. 4. Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. 5. Emmes Corporation, Rockville, MD, USA. 6. Department of Pediatrics and Skaggs School of Pharmacy, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0831, USA. ecapparelli@ucsd.edu.
Abstract
BACKGROUND: Lorazepam is one of the preferred agents used for intravenous treatment of status epilepticus (SE). We combined data from two pediatric clinical trials to characterize the population pharmacokinetics of intravenous lorazepam in infants and children aged 3 months to 17 years with active SE or a history of SE. METHODS: We developed a population pharmacokinetic model for lorazepam using the NONMEM software. We then assessed exploratory exposure-response relationships using the overall efficacy and safety study endpoints, and performed dosing simulations. RESULTS: A total of 145 patients contributed 439 pharmacokinetic samples. The median (range) age and dose were 5.4 years (0.3-17.8) and 0.10 mg/kg (0.02-0.18), respectively. A two-compartment pharmacokinetic model with allometric scaling described the data well. In addition to total body weight (WT), younger age was associated with slightly higher weight-normalized clearance (CL). The following relationships characterized the typical values for the central compartment volume (V1), CL, peripheral compartment volume (V2), and intercompartmental CL (Q), using individual subject WT (kg) and age (years): V1 (L) = 0.879*WT; CL (L/h) = 0.115*(Age/4.7)0.133*WT0.75; V2 (L) = 0.542*V1; Q (L/h) = 1.45*WT0.75. No pharmacokinetic parameters were associated with clinical outcomes. Simulations suggest uniform pediatric dosing (0.1 mg/kg, to a maximum of 4 mg) can be used to achieve concentrations of 50-100 ng/mL in children with SE, which have been previously associated with effective seizure control. CONCLUSIONS: The population pharmacokinetics of lorazepam were successfully described using a sparse sampling approach and a two-compartment model in pediatric patients with active SE.
BACKGROUND: Lorazepam is one of the preferred agents used for intravenous treatment of status epilepticus (SE). We combined data from two pediatric clinical trials to characterize the population pharmacokinetics of intravenous lorazepam in infants and children aged 3 months to 17 years with active SE or a history of SE. METHODS: We developed a population pharmacokinetic model for lorazepam using the NONMEM software. We then assessed exploratory exposure-response relationships using the overall efficacy and safety study endpoints, and performed dosing simulations. RESULTS: A total of 145 patients contributed 439 pharmacokinetic samples. The median (range) age and dose were 5.4 years (0.3-17.8) and 0.10 mg/kg (0.02-0.18), respectively. A two-compartment pharmacokinetic model with allometric scaling described the data well. In addition to total body weight (WT), younger age was associated with slightly higher weight-normalized clearance (CL). The following relationships characterized the typical values for the central compartment volume (V1), CL, peripheral compartment volume (V2), and intercompartmental CL (Q), using individual subject WT (kg) and age (years): V1 (L) = 0.879*WT; CL (L/h) = 0.115*(Age/4.7)0.133*WT0.75; V2 (L) = 0.542*V1; Q (L/h) = 1.45*WT0.75. No pharmacokinetic parameters were associated with clinical outcomes. Simulations suggest uniform pediatric dosing (0.1 mg/kg, to a maximum of 4 mg) can be used to achieve concentrations of 50-100 ng/mL in children with SE, which have been previously associated with effective seizure control. CONCLUSIONS: The population pharmacokinetics of lorazepam were successfully described using a sparse sampling approach and a two-compartment model in pediatric patients with active SE.
Authors: James M Chamberlain; Edmund V Capparelli; Kathleen M Brown; Cheryl W Vance; Kathleen Lillis; Prashant Mahajan; Richard Lichenstein; Rachel M Stanley; Colleen O Davis; Stephen Gordon; Jill M Baren; John N van den Anker Journal: J Pediatr Date: 2011-11-01 Impact factor: 4.406
Authors: Eleonora L Swart; Klaas P Zuideveld; Joost de Jongh; Meindert Danhof; Lambertus G Thijs; Robert M J Strack van Schijndel Journal: Br J Clin Pharmacol Date: 2004-02 Impact factor: 4.335
Authors: Simon N Muchohi; Kenneth Obiero; Charles R J C Newton; Bernhards R Ogutu; Geoffrey Edwards; Gilbert O Kokwaro Journal: Br J Clin Pharmacol Date: 2007-07-17 Impact factor: 4.335
Authors: Sebastiaan C Goulooze; Erwin Ista; Monique van Dijk; Dick Tibboel; Elke H J Krekels; Catherijne A J Knibbe Journal: AAPS J Date: 2021-05-17 Impact factor: 4.009
Authors: Anna C van der Vossen; Merel van Nuland; Erwin G Ista; Saskia N de Wildt; Lidwien M Hanff Journal: Acta Paediatr Date: 2018-03-23 Impact factor: 2.299
Authors: Adam Strzelczyk; Laurent M Willems; Ricardo Kienitz; Lara Kay; Isabelle Beuchat; Sarah Gelhard; Sophie von Brauchitsch; Catrin Mann; Alexandra Lucaciu; Jan-Hendrik Schäfer; Kai Siebenbrodt; Johann-Philipp Zöllner; Susanne Schubert-Bast; Felix Rosenow Journal: CNS Drugs Date: 2022-08-16 Impact factor: 6.497
Authors: Abhishek G Sathe; Richard C Brundage; Vijay Ivaturi; James C Cloyd; James M Chamberlain; Jordan J Elm; Robert Silbergleit; Jaideep Kapur; Lisa D Coles Journal: Clin Transl Sci Date: 2021-05-01 Impact factor: 4.689